ENGOT Cx8/GOG 3024/innovaTV 205: Interim Phase II Results With Tisotumab Vedotin Combinations in Recurrent or Metastatic Cervical Cancer

June 3-7, 2022; Chicago, Illinois
Tisotumab vedotin plus pembrolizumab demonstrated promising, durable antitumor activity with a tolerable safety profile in recurrent or metastatic cervical cancer.
Format: Microsoft PowerPoint (.ppt)
File Size: 199 KB
Released: June 9, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline
Merck Sharp & Dohme Corp.
Seattle Genetics

Related Content

Final OS data for PAOLA-1 phase III trial of maintenance olaparib plus bevacizumab vs placebo plus bevacizumab in newly diagnosed ovarian cancer, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Released: September 27, 2022

Downloadable slideset updated with highlights of key gynecologic oncology studies presented at conferences throughout 2022, from Clinical Care Options (CCO)

Jubilee Brown, MD person default Elisabeth Diver, MD person default Alexandra Leary, MD, PhD Domenica Lorusso, MD, PhD David Scott Miller, MD, FACOG, FACS Angeles Alvarez Secord, MD, MHSc Released: September 26, 2022

7-year follow-up from phase III SOLO-1 trial of maintenance olaparib vs placebo in newly diagnosed advanced ovarian cancer, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Released: September 15, 2022

Interactive online tool with expert management recommendations for selecting therapy for women with advanced endometrial cancer, from Clinical Care Options (CCO)

Maria Bell, MD, MPH, MBA Hye Sook Chon, MD Linda R. Duska, MD, MPH Ritu Salani, MD, MBA Shannon N. Westin, MD, MPH Released: September 13, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings